Molecular immunology
Cure8 research brief
Why This Matters
The study identifies CDK9 inhibition as a way to reduce IL‑6/STAT3 signaling and protect the colonic epithelial barrier in preclinical models, suggesting a potential new therapeutic approach for ulcerative colitis focused on transcriptional control of inflammation.
Who Should Pay Attention
Researchers, translational scientists, and clinicians interested in IBD drug discovery and mucosal healing
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The experiments used an established chemical colitis model (DSS) and cultured intestinal epithelial cells to test LDC000067, a selective CDK9 inhibitor.
Treated mice had smaller clinical scores, preserved colon length, better histology, and more goblet cells; epithelial ultrastructure and tight junction proteins (ZO‑1, occludin) were improved in treated animals and cells.
Mechanistic data in the paper link CDK9 inhibition to reduced RNAPII Ser2 phosphorylation, lower IL‑6 secretion, and decreased STAT3 phosphorylation and nuclear translocation. The work is preclinical (mouse and cell experiments) and explores a transcriptional-regulation target (CDK9) rather than an approved therapy.
It points to a possible new target for promoting mucosal healing, but it does not provide human safety or efficacy data.
Keep In Mind
Findings are from DSS-induced colitis in mice and LPS-stimulated Caco-2 cells (preclinical models). The paper is a basic-science study and does not include human data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMolecular immunology
AuthorsZhao W, Wu Y, Zhao N +4 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 22, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Trichostatin A ameliorates ulcerative colitis via the SERPINB5-mediated MMP9/RLN2 signaling pathway.
The paper identifies a molecular pathway (SERPINB5–MMP9–RLN2) by which the HDAC inhibitor trichostatin A reduced inflammation and protected the intestinal barrier in mouse and cell models of ulcerative colitis,...
Chishizhi Yuyuliang Decoction Ameliorates Ulcerative Colitis in Mice by Promoting Colonic Epithelial Mucosal Healing via the CAV1/FA Axis.
This paper identifies a herbal formula that improved inflammation and epithelial barrier repair in a mouse colitis model and highlights specific molecular pathways (CAV1/FAK/paxillin and metabolite pathways) that might...
KARAP Exacerbates Intestinal Inflammation Through Promoting Kyn-AhR-dependent Neutrophil Activation in Ulcerative Colitis.
The paper identifies a neutrophil-related immune pathway (KARAP → IDO1–kynurenine → AhR → IL-22) that contributes to mucosal inflammation in ulcerative colitis, suggesting a potential new target for research and drug...